Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Summary
The purpose of this study is to investigate the safety, pharmacokinetics and preliminary efficacy of combinations treatment of ruxolitinib with 3 novel compounds: siremadlin, crizanlizumab and MBG453 in myelofibrosis (MF) subjects.
Study Design
Conditions
Myelofibrosis
Intervention
Ruxolitinib, Siremadlin, Crizanlizumab, MBG453
Status
Not yet recruiting
Source
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT04097821
- ClinicalTrials.gov processed this data on September 25, 2019
Published on BioPortfolio: 2019-09-26T05:42:43-0400
Clinical Trials
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.
This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
The purpose of this study was to evaluate the effect of an alternative dosing strategy of ruxolitinib in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PP...
Study of Ruxolitinib for Patients With Myelofibrosis (MF)
The goal of this clinical research study is to collect data about the long term safety and tolerability of ruxolitinib when given to patients with MF.
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Based on the investigators' preclinical data, the combination of pevonedistat and ruxolitinib may provide greater clinical responses in patients with myelofibrosis compared to ruxolitinib ...
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis.
PubMed Articles
To estimate survival in Swedish and Norwegian myelofibrosis (MF) patients who received ruxolitinib.
Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or...
Leukemic transformation is an unfavorable event emerging in a minority of patients with myelofibrosis (MF) and carrying a poor prognosis. Patients with post-MF acute myeloid leukemia (AML) may be trea...
Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course. Panob...
Intestinal Behçet's Disease with Primary Myelofibrosis Involving Trisomy 8.
Behçet's disease (BD) is a disorder characterized by systemic inflammation of multiple organs, including the intestines. Several studies have reported a relationship between myelodysplastic syndrome ...
Medical and Biotech [MESH] Definitions
Primary Myelofibrosis
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Leukemia, Megakaryoblastic, Acute
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
More From BioPortfolio on "Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients"
Quick Links
Advanced Search |
Login |
Subscribe |
RSS 
BioPortfolio Twitter Channels (200+ Accounts)
LinkedIn